Lv32
400 积分 2022-11-04 加入
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
2小时前
已完结
Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non–muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial
19小时前
已完结
Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non–muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial
19小时前
已完结
Uromonitor®: Clinical Validation and Performance Assessment of a Urinary Biomarker within the Surveillance of Non-Muscle Invasive Bladder Cancer Patients
19小时前
已完结
Results of the Prospective Randomized UroFollow Trial Comparing Marker-guided Versus Cystoscopy-based Surveillance in Patients with Low/Intermediate-risk Bladder Cancer
19小时前
已完结
[Guidelines on clinical practice of molecular tests in non-small cell lung cancer in China (2024 version)]
1个月前
已完结
Consensus on the lung cancer management after third-generation EGFR-TKI resistance
1个月前
已完结
NGS and FISH for MET amplification detection in EGFR TKI resistant non-small cell lung cancer (NSCLC) patients: A prospective, multicenter study in China
1个月前
已完结
Consensus on the lung cancer management after third-generation EGFR-TKI resistance
1个月前
已完结
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
1个月前
已完结
皖公网安备34019202002308
